Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis
BackgroundClear cell adenocarcinoma (CCA) is considered a relatively rare tumor with a glycogen-rich phenotype. The prognosis of CCA patients is unclear. In this study, recent trends in the epidemiological and prognostic factors of CCA were comprehensively investigated.MethodsPatients with CCA from...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-02-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.762589/full |
| _version_ | 1819279318009774080 |
|---|---|
| author | Yadong Guo Yadong Guo Anil Shrestha Niraj Maskey Niraj Maskey Xiaohui Dong Zongtai Zheng Zongtai Zheng Fuhan Yang Fuhan Yang Ruiliang Wang Ruiliang Wang Wenchao Ma Wenchao Ma Ji Liu Ji Liu Cheng Li Cheng Li Wentao Zhang Wentao Zhang Shiyu Mao Shiyu Mao Aihong Zhang Shenghua Liu Shenghua Liu Xudong Yao Xudong Yao |
| author_facet | Yadong Guo Yadong Guo Anil Shrestha Niraj Maskey Niraj Maskey Xiaohui Dong Zongtai Zheng Zongtai Zheng Fuhan Yang Fuhan Yang Ruiliang Wang Ruiliang Wang Wenchao Ma Wenchao Ma Ji Liu Ji Liu Cheng Li Cheng Li Wentao Zhang Wentao Zhang Shiyu Mao Shiyu Mao Aihong Zhang Shenghua Liu Shenghua Liu Xudong Yao Xudong Yao |
| author_sort | Yadong Guo |
| collection | DOAJ |
| description | BackgroundClear cell adenocarcinoma (CCA) is considered a relatively rare tumor with a glycogen-rich phenotype. The prognosis of CCA patients is unclear. In this study, recent trends in the epidemiological and prognostic factors of CCA were comprehensively investigated.MethodsPatients with CCA from years 2000 to 2016 were identified from the Surveillance, Epidemiological, and End Results (SEER) database. Relevant population data were used to analyze the rates age-adjusted incidence, age-standardized 3-year and 5-year relative survivals, and overall survival (OS).ResultsThe age-adjusted incidence of CCA increased 2.7-fold from the year 2000 (3.3/100,000) to 2016 (8.8/100,000). This increase occurred across all ages, races, stages, and grades. Of all these subgroups, the increase was largest in the grade IV group. The age-standardized 3-year and 5-year relative survivals increased during this study period, rising by 9.1% and 9.5% from 2000 to 2011, respectively. Among all the stages and grades, the relative survival increase was greatest in the grade IV group. According to multivariate analysis of all CCA patients, predictors of OS were: age, gender, year of diagnosis, marital status, race, grade, stage, and primary tumor site (P < 0.001). The OS of all CCA patients during the period 2008 to 2016 was significantly higher than that from 2000 to 2007 (P < 0.001).ConclusionsThe incidence of CCA and survival of these patients improved over time. In particular, the highest increases were reported for grade IV CCA, which may be due to an earlier diagnosis and improved treatment. |
| first_indexed | 2024-12-24T00:25:59Z |
| format | Article |
| id | doaj.art-4beff596fa6f4dfda735362ef37b9997 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-24T00:25:59Z |
| publishDate | 2022-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-4beff596fa6f4dfda735362ef37b99972022-12-21T17:24:26ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-02-011310.3389/fendo.2022.762589762589Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER AnalysisYadong Guo0Yadong Guo1Anil Shrestha2Niraj Maskey3Niraj Maskey4Xiaohui Dong5Zongtai Zheng6Zongtai Zheng7Fuhan Yang8Fuhan Yang9Ruiliang Wang10Ruiliang Wang11Wenchao Ma12Wenchao Ma13Ji Liu14Ji Liu15Cheng Li16Cheng Li17Wentao Zhang18Wentao Zhang19Shiyu Mao20Shiyu Mao21Aihong Zhang22Shenghua Liu23Shenghua Liu24Xudong Yao25Xudong Yao26Department of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, ChinaUrologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, National Academy of Medical Sciences, Bir Hospital, Kathmandu, NepalDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, ChinaUrologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of General Medical, Shanghai Fourth People’s Hospital, Tongji University, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, ChinaUrologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, ChinaUrologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, ChinaUrologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, ChinaUrologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, ChinaUrologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, ChinaUrologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, ChinaUrologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, ChinaUrologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Medical Statistics, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, ChinaUrologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaDepartment of Urology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, ChinaUrologic Cancer Institute, Tongji University School of Medicine, Shanghai, ChinaBackgroundClear cell adenocarcinoma (CCA) is considered a relatively rare tumor with a glycogen-rich phenotype. The prognosis of CCA patients is unclear. In this study, recent trends in the epidemiological and prognostic factors of CCA were comprehensively investigated.MethodsPatients with CCA from years 2000 to 2016 were identified from the Surveillance, Epidemiological, and End Results (SEER) database. Relevant population data were used to analyze the rates age-adjusted incidence, age-standardized 3-year and 5-year relative survivals, and overall survival (OS).ResultsThe age-adjusted incidence of CCA increased 2.7-fold from the year 2000 (3.3/100,000) to 2016 (8.8/100,000). This increase occurred across all ages, races, stages, and grades. Of all these subgroups, the increase was largest in the grade IV group. The age-standardized 3-year and 5-year relative survivals increased during this study period, rising by 9.1% and 9.5% from 2000 to 2011, respectively. Among all the stages and grades, the relative survival increase was greatest in the grade IV group. According to multivariate analysis of all CCA patients, predictors of OS were: age, gender, year of diagnosis, marital status, race, grade, stage, and primary tumor site (P < 0.001). The OS of all CCA patients during the period 2008 to 2016 was significantly higher than that from 2000 to 2007 (P < 0.001).ConclusionsThe incidence of CCA and survival of these patients improved over time. In particular, the highest increases were reported for grade IV CCA, which may be due to an earlier diagnosis and improved treatment.https://www.frontiersin.org/articles/10.3389/fendo.2022.762589/fullclear cell adenocarcinomaSEER databaseincidencesurvivalglycogen-rich phenotype |
| spellingShingle | Yadong Guo Yadong Guo Anil Shrestha Niraj Maskey Niraj Maskey Xiaohui Dong Zongtai Zheng Zongtai Zheng Fuhan Yang Fuhan Yang Ruiliang Wang Ruiliang Wang Wenchao Ma Wenchao Ma Ji Liu Ji Liu Cheng Li Cheng Li Wentao Zhang Wentao Zhang Shiyu Mao Shiyu Mao Aihong Zhang Shenghua Liu Shenghua Liu Xudong Yao Xudong Yao Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis Frontiers in Endocrinology clear cell adenocarcinoma SEER database incidence survival glycogen-rich phenotype |
| title | Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis |
| title_full | Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis |
| title_fullStr | Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis |
| title_full_unstemmed | Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis |
| title_short | Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis |
| title_sort | recent trends in the incidence of clear cell adenocarcinoma and survival outcomes a seer analysis |
| topic | clear cell adenocarcinoma SEER database incidence survival glycogen-rich phenotype |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.762589/full |
| work_keys_str_mv | AT yadongguo recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT yadongguo recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT anilshrestha recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT nirajmaskey recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT nirajmaskey recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT xiaohuidong recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT zongtaizheng recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT zongtaizheng recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT fuhanyang recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT fuhanyang recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT ruiliangwang recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT ruiliangwang recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT wenchaoma recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT wenchaoma recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT jiliu recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT jiliu recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT chengli recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT chengli recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT wentaozhang recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT wentaozhang recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT shiyumao recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT shiyumao recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT aihongzhang recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT shenghualiu recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT shenghualiu recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT xudongyao recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis AT xudongyao recenttrendsintheincidenceofclearcelladenocarcinomaandsurvivaloutcomesaseeranalysis |